Nobody can argue, legal marijuana is a huge growth industry, in every sense of the word. Legal marijuana sales reached $6.9 billion in 2016, and many experts predict that number may triple now that California has voted to legalize recreational use. Bloomberg forecasts that the industry may reach $50 billion in the next 10 years ($22.8 billion by 2020).
Some investors are starting to wonder if there’s a way they can make money in this sector?
Well yes there is, or at least there are stocks they can buy if they want to bet on the industry’s continued growth, which every analyst out there agrees it will.
Many Marijuana Stocks have already skyrocketed, so the trick is finding the ‘budding’ stocks in this sector that are set to launch, so you can maximize your gains.
While medical and/or recreational marijuana is legal in 28 states and the District of Columbia, it remains illegal under federal laws which were generally not enforced during the Obama administration. One of the biggest risks facing the industry today is that President Donald Trump and Attorney General Jeff Sessions may begin enforcing those laws which could conceivably cause the entire industry to shut down. So while there may a big up side to investing in the legal marijuana industry, you could also lose big depending how things play out. Keep that in mind when deciding whether and how much to invest.
Here are some of cannabis-related stocks we think have solid potential in the very near future:
1. MYM Nutraceuticals (MYMMF)
MYM Nutraceuticals is a bio-pharmaceutical company focused on production, distribution, innovation, technology and branded products related to the marijuana industry. It’s a unique formula of natural, medicinal solutions supported by integrated operations.
MYM Nutraceuticals (MYMMF) is a well-positioned company in the marijuana space taking an integrated approach with a long-term perspective. The company is a serious contender with current operations, experienced medical management and a host of early successes that put its stock on track for major gains.
MYM is based in Canada, where legislation is guaranteed under Government by 2018, and has expansion underway in the USA with their CBD line, Hempmed. They recently listed their shares on the OTCQB. Taking into consideration the coming legislation in Canada, the Growth in the USA and the new trading listing in the states, your timing is bang-on to pick some MYMMF up and watch it grow.
For more information on MYM Nutraceuticals, review this research report by clicking here
2. Medicine Man Technologies (MDCL)
Medicine Man Technologies is a consulting and licensing services company that serves cultivators, dispensaries, vendors, and investors. Its co-founder also co-founded Colorado’s largest marijuana cultivator and retailer. Medicine Man Technologies has a market cap of only $18 million, and it lost about 2 cents per share last fiscal year. But sales have been growing at a rapid clip, and the company may have real potential.
3. AbbVie (ABBV)
AbbVie was spun off from Abbott Labs in 2013 as a biopharmaceutical firm. It has 28,000 employees. Although it’s not cannabis-focused, the company already has one cannabis-based drug, called Marinol, approved by the FDA. AbbVie has a market cap of $101.7 billion, a price to earnings (P/E) ration of 16.8, and earnings per share (EPS) of $3.65 as of the end of 2016. In February, it announced a stock buyback.
Source: Westbrook Radio
http://WestbrookRadio.com
This publication is not an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. westbrookradio. com is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been compensated twelve thousand dollars from MYM Nutraceuticals as an advertising budget. The owner/operator of westbrookradio have also purchased two thousand shares of MYM in the open market and have no plans of selling these shares in the next 72 hours.There may be other 3rd parties who may have shares in MYM, and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.